- Imeik Technology reported a net income of 443.7 million yuan for the first quarter of 2025.
- The company generated revenue of 663.5 million yuan during the same period.
- Analyst ratings for Imeik Technology include 32 buy recommendations, 2 hold ratings, and no sell ratings, indicating strong market confidence.
A look at Imeik Technology Development C Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 5 | |
| Resilience | 5 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 4.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Imeik Technology Development C is positioned for a bright future according to the Smartkarma Smart Scores. With top-notch ratings in Growth, Resilience, and Momentum, the company is poised for long-term success. Its robust Growth score reflects strong potential for expansion and innovation, while high marks in Resilience indicate a solid foundation to withstand market fluctuations. Furthermore, Imeik Technology Development C‘s impressive Momentum score suggests strong market performance and investor interest.
Operating in the biomedical sector, Imeik Technology Development C specializes in manufacturing and distributing a range of crucial products like sodium hyaluronate, collagens, and medical devices. With a balanced mix of positive ratings across metrics such as Value, Dividend, Growth, Resilience, and Momentum, Imeik Technology Development C appears well-positioned to thrive in the competitive industry landscape.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
